CLINICAL ROLE -
Oncology Biosimilars Bring Hope to Patients with Cancer
Biosimilars for rituximab, trastuzumab, and bevacizumab are currently approved for use in the European Union.
Read More
Combo Therapy Well-Tolerate in RAS Wild-Type Metastatic Colorectal Cancer
Cetuximab (Erbitux) with pembrolizumab (Keytruda) shows promise in patients with mCRC.
Combination Therapy Shows Antitumor Activity in Advanced Gastric, GEJ Adenocarcinoma
A combination VEGFR-2 inhibitor plus an anti–PD-L1 agent demonstrated antitumor activity in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.